Xenetic Biosciences, Inc. Enters Into Asset Purchase Agreement With Financing Component for the Rights to Develop, Market and License Oncologic Drug Candidate Virexxa™
November 16, 2015 12:09 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO) (the “Company”), a biopharmaceutical company focused on developing next-generation biologic drugs and novel...
Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements
October 07, 2015 07:04 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., Oct. 07, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO) (the “Company”), a biopharmaceutical company focused on developing next-generation biologic drugs and novel...
Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia
September 16, 2015 07:00 ET
|
Xenetic Biosciences, Inc.
Trial expands into South Africa Compound uses Patented PolyXen® Technology for Recombinant Erythropoietin LEXINGTON, Mass., Sept. 16, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc....
Xenetic Biosciences (XBIO) Contracts With Baxter International Inc Have Been Assigned to Baxalta Incorporated Following the Company Spin Out
September 09, 2015 07:00 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., Sept. 09, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology...
Xenetic Biosciences, Inc. Launches Digital Corporate Communication Channels
September 02, 2015 07:29 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., Sept. 02, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology...
Xenetic Biosciences Reports Phase 2 Data on Drug Candidate ErepoXen(R) for Anemia
July 14, 2015 06:00 ET
|
Xenetic Biosciences, Inc.
Hemoglobin Levels Rose and were Maintained in Therapeutic Range ErepoXen was Generally Well Tolerated With No Significant Treatment-related Adverse Events Compound uses Patented PolyXen® Technology...
Xenetic Biosciences Completes $3,000,000 Bridge Note Financing
July 08, 2015 12:28 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., July 08, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (“Xenetic” or the “Company”) (OTCQB:XBIO), a biopharmaceutical company focused on developing next-generation biologic...
Xenetic Biosciences Announces Board Change
April 21, 2015 18:05 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., April 21, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology...
Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen(R)
June 30, 2014 07:00 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology...
Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R)
June 11, 2014 07:00 ET
|
Xenetic Biosciences, Inc.
LEXINGTON, Mass., June 11, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology...